Discover more insights into Reference Adalimumab

Keywords frequently search together with Reference Adalimumab

Narrow sentence examples with built-in keyword filters

More Reference Adalimumab sentence examples
10.1093/rheumatology/keab460

Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomised study in rheumatoid arthritis.


More Reference Adalimumab sentence examples
10.1007/s40259-021-00470-1

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)



Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double‐blind, parallel‐controlled, phase 1 study



SWITCHING BETWEEN REFERENCE ADALIMUMAB AND BIOSIMILARS IN CHRONIC IMMUNE-MEDIATED INFLAMMATORY DISEASES: A SYSTEMATIC LITERATURE REVIEW.


More Reference Adalimumab sentence examples
10.1136/ANNRHEUMDIS-2021-EULAR.325

AB0198 EFFICACY AND SAFETY AFTER TRANSITION FROM REFERENCE ADALIMUMAB TO CT-P17 (ADALIMUMAB BIOSIMILAR: 100 MG/ML) IN COMPARISON WITH THE MAINTAINED TREATMENT (CT-P17 OR REFERENCE ADALIMUMAB) IN PATIENTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS: 1-YEAR RESULT



An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability


More Reference Adalimumab sentence examples
10.1093/ecco-jcc/jjab076.592

P469 The PROPER study: interim analysis of a pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn’s disease


More Reference Adalimumab sentence examples
10.1007/s12325-021-01929-x

Investigation of the Physicochemical and Biological Stability of the Adalimumab Biosimilar CT-P17


More Reference Adalimumab sentence examples
10.1186/s13075-020-02394-7

Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study


More Reference Adalimumab sentence examples
10.1136/ANNRHEUMDIS-2019-EULAR.8512

SP0014 THE LATEST NEWS ON BIOSIMILARS TREATMENT


More Reference Adalimumab sentence examples
10.1136/ANNRHEUMDIS-2019-EULAR.4220

FRI0088 SAFETY, IMMUNOGENICITY AND EFFICACY OF THE PROPOSED BIOSIMILAR MSB11022 (MODIFIED FORMULATION) COMPARED WITH ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS: AURIEL-RA, A RANDOMISED, DOUBLE-BLIND, PHASE III STUDY


More Reference Adalimumab sentence examples
10.1007/s40259-019-00335-8

FKB327: An Adalimumab Biosimilar


More Reference Adalimumab sentence examples
10.1007/s10067-019-04679-y

Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis



Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data



AURIEL‐PsO: a randomized, double‐blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis


More Reference Adalimumab sentence examples
10.1136/ANNRHEUMDIS-2019-EULAR.2373

AB0404 VALIDATION OF A THERAPEUTIC DRUG MONITORING TEST TO MEASURE THE ADALIMUMAB BIOSIMILAR SB5 IN COMPARISON WITH THE REFERENCE ADALIMUMAB



SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis


More Reference Adalimumab sentence examples
10.1080/1744666X.2020.1682553

Biosimilars for the treatment of psoriatic arthritis


More Reference Adalimumab sentence examples
10.1016/j.biologicals.2018.12.002

Demonstration of functional similarity of a biosimilar adalimumab SB5 to Humira®.


More Reference Adalimumab sentence examples
10.1080/14712598.2019.1571580

GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods


More Reference Adalimumab sentence examples
10.1136/annrheumdis-2019-eular.1909

FRI0086 CHINA-MANUFACTURED ADALIMUMAB BIOSIMILAR, HLX03, DEMONSTRATED PHARMACOKINETIC EQUIVALENCE AND COMPARABLE SAFETY TO REFERENCE ADALIMUMAB


Learn more from Reference Adalimumab


Reference Adalimumab
Encyclopedia